Review Article
ROS-Mediated Therapeutic Strategy in Chemo-/Radiotherapy of Head and Neck Cancer
Table 5
Combination treatment of PDT with chemotherapy drugs in HNC.
| | Site | Model | Photosensitizer/laser irradiation | Cotherapy | ROS detection | Effect | Mechanisms | Reference |
| | Larynx | In vitro
(AMC-HN3 cell)
In vivo
(AMC-HN3 xenograft nude mice | Radachlorin (0.9 J/cm2) | +Carboplatin | DCFH-DA confocal microscope, flow cytometry | Synergistic effects: reduce side effect | ↑cytochrome c ↓EGFR, ↑ROS | [258] |
| | Larynx | In vitro
(Hep-2 cell) | mTHPC (2 J/cm2) | +Cisplatin (5 μM) | — | Synergistic effects | ↓Bcl-2, ↓PD-L1 ↓ATG-7, ↓LC3-II/LC3-I | [259] |
| | Oral cavity | In vitro
(BHY cell) | mTHPC (1.8 J/cm2) | +Oxaliplatin (0.1-100 μM) | DCFH-DA flow cytometry | Synergistic effects | ↑ROS, ↑S-phase arrest | [260] |
| | Esophagus | In vitro
(KYSE-70 cell) | mTHPC (1.8 J/cm2) | +Cisplatin (0.01-50 μM) | DCFH-DA flow cytometry | Synergistic effects | ↑ROS | [260] |
| | Head and neck | In vitro
(cisplatin-resistant SQ20B and JSQ3 cell and cisplatin-sensitive HNSCC135 and SCC61 cell)
In vivo
(SQ20B xenograft nude mice) | Pyrolipid (54 J/cm2) | +Cisplatin (0.5 mg/kg) | — | Synergistic effects: enhance apoptosis | ↑IL-6, ↑TNF-α, ↑IFN-γ | [261] |
|
|
Notes. DCFH-DA: 2 ,7 -dichlorofluorescein diacetate; mTHPC: meta-Tetra (hydroxyphenyl) chlorin; EGFR: epidermal growth factor receptor; Bcl-2: B-cell lymphoma-2; ROS: reactive oxygen species; LC3: microtubule-associated protein light chain 3; ATG-7: autophagy-related 7; TNF- α: tumor necrosis factor- α; IL-6: interleukin-6; IFN- γ: interferon- γ. |
